Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
November 07, 2023 16:35 ET
|
Lumos Pharma, Inc.
-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – -- OraGrowtH210 Trial Results Show...
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
November 07, 2023 16:01 ET
|
Lumos Pharma, Inc.
OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD...
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
September 26, 2023 09:00 ET
|
Lumos Pharma, Inc.
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children Analysis Shows Annualized Height Velocity Increased ~62% Compared to BaselineData Support...
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
September 14, 2023 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...
Lumos Pharma Announces Participation in Investor Conferences in September
September 07, 2023 16:34 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
August 22, 2023 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
August 09, 2023 16:01 ET
|
Lumos Pharma, Inc.
Confirms Timing for Primary Outcome Data Readout for two Phase 2 OraGrowtH Trials in Q4 2023Late Breaking Abstract Accepted for Oral Presentation at ESPE 2023Encouraging Interim Data from OraGrowtH...
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
July 26, 2023 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
July 12, 2023 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Lumos Pharma Announces Departure of Chief Medical Officer
June 28, 2023 16:01 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone...